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New  guidelines  from  the  European  Society  of  Cardiology  (ESC)  on  the  management  of  car-
diovascular  diseases  during  pregnancy  were  published  recently  in  the  December  2011  issue
of  the  European  Heart  Journal  [1].  This  version  differs  markedly  from  the  previous  guide-
lines  on  the  same  topic,  published  in  2003  [2].  This  is  not  the  consequence  of  major  changes
in  knowledge  over  the  past  decade,  but  rather  is  related  to  the  way  in  which  these  new
recommendations  are  presented.  Recommendations  are  difﬁcult  to  elaborate  in  the  ﬁeld
of  cardiovascular  diseases  during  pregnancy  because  situations  are  highly  heterogeneous
and  most  data  come  from  observational  series  with  an  inherent  low  level  of  evidence.
Nevertheless,  this  is  the  ﬁrst  time  that  graded  recommendations  have  been  made  avail-
able  in  this  ﬁeld.  The  low  level  of  underlying  evidence  is  illustrated  by  the  fact  that  nearly
all  of  the  recommendations  are  a  level  of  evidence  C.  It  should  be  stressed  that  speciﬁc
American  College  of  Cardiology/American  Heart  Association  guidelines  are  not  available
for  cardiovascular  diseases  during  pregnancy.
Besides  speciﬁc  sections  according  to  the  different  types  of  heart  valve  disease,  the
section  ‘‘General  Considerations’’  is  much  more  developed  than  in  the  previous  guidelines
and  provides  detailed  information  on  the  speciﬁcities  of  investigations  and  interventions
during  pregnancy.  In  clinical  practice,  the  general  approach  proposed  for  risk  stratiﬁcation
requires  particular  attention.  Even  if  risk  stratiﬁcation  needs  to  be  further  reﬁned  accor-
ding  to  the  speciﬁcities  of  each  type  of  heart  disease,  it  is  important  that  practitioners  who
are  not  familiar  with  heart  disease  in  pregnant  women  can  easily  identify  those  in  whom
pregnancy  may  compromise  maternal  and/or  foetal  life.  In  these  cases,  women  should  be
made  aware  of  the  risks  of  pregnancy,  treated  before  pregnancy  if  indicated  and,  if  seen
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uring  pregnancy,  orientated  towards  specialized  teams
omprising  obstetricians,  cardiologists  and  anaesthesio-
ogists  with  speciﬁc  experience  in  the  management  of  preg-
ant  patients  with  heart  disease.
A  particular  feature  of  heart  diseases  during  pregnancy
s  the  impact  of  epidemiology.  Advances  in  the  management
f  congenital  heart  disease  explain  why  a  high  number  of
omen  now  reach  childbearing  age.  Thus  congenital  heart
isease  is  now  the  most  frequent  heart  disease  in  preg-
ant  women  in  Western  countries,  accounting  for  70—80%
f  all  cardiovascular  disease  during  pregnancy.  Conversely,
heumatic  heart  disease  remains  the  leading  cardiovascular
isease  in  developing  countries  [3].  This  also  explains  why
heumatic  heart  disease  is  still  the  second  most  frequent
ause  of  heart  disease  during  pregnancy  in  Western  coun-
ries,  accounting  for  approximately  15%  of  cases,  mainly
ecause  of  population  migration.  It  is  estimated  that  appro-
imately  1%  of  pregnancies  are  complicated  by  heart  disease
n  Europe,  accounting  for  50,000  pregnancies  per  year  in  the
uropean  Union  [4].  In  a  registry  from  the  United  Kingdom,
eart  disease  was  found  to  be  the  leading  cause  of  death
uring  pregnancy,  with  a  constant  increase  of  the  number
f  cases  over  the  past  20  years  [4].
Congenital  heart  disease  is  a  particularly  heterogeneous
ntity,  not  only  because  of  the  diversity  of  the  lesions
nvolved  but  also  because  of  the  considerable  discrepan-
ies  in  pregnancy-related  risks,  which  range  from  low  risk
n  left  to  right  shunts  to  a  30—40%  maternal  mortality  in
isenmenger  syndrome.  This  information  highlights  the  need
or  a  tailored  approach  by  practitioners  having  a  particular
xpertise  in  congenital  heart  disease  in  adults  [5].
It  is  important  to  draw  attention  to  the  persistent  bur-
en  of  rheumatic  heart  disease  during  pregnancy  because
f  the  trend  towards  a  decreased  awareness  in  Western
ountries.  The  diagnosis  of  rheumatic  heart  disease,  in  par-
icular  mitral  stenosis,  should  not  be  missed  in  young  women
iven  the  high  risk  of  pregnancy-related  complications  and
he  availability  of  percutaneous  mitral  commissurotomy
nabling  a  safe  and  effective  treatment  even  during  preg-
ancy.  Maternal  mortality  is  now  low  (less  than  3%)  in
regnant  women  with  mitral  stenosis  in  Western  countries
6—8].  In  contrast,  15  pregnancy-related  deaths  occurred
mong  32  women  with  decompensated  mitral  stenosis  in
 recent  series  from  sub-Saharan  Africa  [9].  Regarding  the
ase  of  previously  operated  patients,  the  ESC  guidelines
tress  the  high  risk  related  to  pregnancy  in  women  with
echanical  heart  valve  prosthesis.  A  number  of  observa-
ional  series  have  reported  high  risks  of  thromboembolism
hatever  the  anticoagulation  regimen  used.  No  anticoagu-
ant  therapy  is  deﬁnitely  favoured  for  the  ﬁrst  trimester  and
he  decision  should  be  individualized.  Overall,  the  European
oint  of  view  is  less  restrictive  than  recommendations  from
he  US  with  regard  to  the  use  of  vitamin  K  antagonists  in
regnant  women  with  a  mechanical  prosthesis  [10,11].
Cardiomyopathies  are  less  frequent  than  other  heart  dis-
ases  but  present  a  particular  entity.  Unlike  other  heart
iseases,  peripartum  cardiomyopathy  seems  to  be  a  direct
onsequence  of  pregnancy  instead  of  the  decompensation
f  a  previous  heart  disease  due  to  the  haemodynamic
tress  inherent  to  pregnancy  [12]. Recent  data  suggest  that
etabolites  of  prolactine  may  play  a  role  in  the  pathophy-
iology  of  peripartum  cardiomyopathy  [13]. However,  at  the
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resent  time,  the  management  of  peripartum  cardiomyopa-
hy  remains  based  on  a  non-speciﬁc  therapy  of  heart  failure
ue  to  systolic  dysfunction.  Complications  are  rare  with
ypertrophic  cardiomyopathy,  provided  functional  tolerance
as  good  before  pregnancy.
Coronary  artery  disease  is  rare  during  pregnancy  although
ts  frequency  is  increasing  and  it  carries  a  poor  progno-
is  [14]. Acute  coronary  syndromes  should  be  managed
nvasively  in  most  cases,  with  appropriate  precautions  to
inimize  radiation  during  percutaneous  coronary  interven-
ions.
Arrhythmias  are  frequently  associated  with  structural
eart  disease,  which  is  the  main  determinant  of  progno-
is.  Electric  cardioversion  can  be  safely  performed  at  each
tage  of  pregnancy.  Drug  therapy  should  be  conducted  with
aution.
Hypertension  is  frequent,  occurring  in  6—15%  of  preg-
ancies,  and  is  a  heterogeneous  entity.  In  pre-eclampsia,
ypertension  is  only  a  marker  of  a  systemic  disorder
nd  the  treatment  is  timely  induction  of  delivery.  In
re-existing  hypertension  and  gestational  hypertension,
omplications  are  rare  for  mild-to-moderate  hypertension
140—160/90—110  mmHg).  Drug  therapy  is  recommended
hen  blood  pressure  is  more  than  150/95  mmHg  and
mergency  hospitalisation  is  needed  when  more  than
70/110  mmHg.  Alpha-methyldopa  remains  the  ﬁrst  choice
edication,  followed  by  labetalol  and  then  dihydropiridines.
Risk  stratiﬁcation  for  venous  thromboembolism  is
ecommended  in  all  pregnant  women  and  prevention  should
e  adapted  to  the  individual  risk  level  (early  mobiliza-
ion,  compression  stockings,  antenatal  and  postpartum
ow-molecular-weight  heparin).
Finally,  these  new  ESC  guidelines  provide  a  comprehen-
ive  table  reviewing  cardiovascular  drugs,  ranked  according
o  their  safety  proﬁle  during  pregnancy.
Despite  the  lack  of  strong  underlying  evidence  in  most
elds,  these  guidelines  from  the  ESC  provide  useful  infor-
ation  for  the  clinician  in  facilitating  an  overall  and
isease-speciﬁc  approach.  This  is  particularly  needed  given
he  heterogeneity  of  heart  diseases  and  associated  risks
uring  pregnancy.  These  guidelines  stress  the  need  for  inter-
isciplinary  management  at  each  stage  of  pregnancy,  in
articular  during  the  peripartum  period,  involving  cardiolo-
ists,  obstetricians  and  anaesthesiologists.  When  pregnancy
s  at  high  risk,  women  should  be  managed  in  specialized  cen-
res,  if  possible  with  on-site  cardiovascular  surgery  facili-
ies.  Ideally,  counselling  should  start  before  pregnancy,
hereby  leading  to  prophylactic  interventions  if  indicated.
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